drugset
drugset / Trial / NCT02283658

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02283658 ↗

Phase 2 Completed 20 enrolled Mayo Clinic National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This pilot, phase II trial studies how well everolimus and letrozole work in treating patients with hormone receptor positive ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back. Everolimus and letrozole may stop the growth of tumor cells by blocking some the enzymes needed for cell growth.

Timeline

Start
2014-11-14
Primary completion
2016-06-15
Completion
2018-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule — Oral
Subject Letrozole Other / unclassified — Oral

Indications

fallopian tube carcinoma ovarian endometrioid adenocarcinoma ovarian germ cell tumor ovarian seromucinous carcinoma ovarian serous cystadenocarcinoma ovarian serous surface papillary adenocarcinoma primary peritoneal carcinoma undifferentiated ovarian carcinoma